{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:05:54Z","timestamp":1789070754508,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.msard.2019.101873","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T01:59:08Z","timestamp":1574647148000},"page":"101873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis"],"prefix":"10.1016","volume":"38","author":[{"given":"Maged","family":"abdel Naseer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amany Mahmoud","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Ahmed","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2586-9653","authenticated-orcid":false,"given":"Amr M","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.msard.2019.101873_bib0001","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00415-003-1041-0","article-title":"Nitric oxide as an activity marker in multiple sclerosis","volume":"250","author":"Acar","year":"2003","journal-title":"J. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.101873_bib0002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0009-8981(03)00229-8","article-title":"CSF and serum orosomucoid (\u03b1-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients","volume":"334","author":"Adam","year":"2003","journal-title":"Clinica Chimica Acta"},{"issue":"9","key":"10.1016\/j.msard.2019.101873_bib0003","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/brain\/awq192","article-title":"Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis","volume":"133","author":"Baranzini","year":"2010","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.msard.2019.101873_bib0004","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2741\/1268","article-title":"Nitric oxide neurotoxicity in neurodegenerative diseases","volume":"9","author":"Boje","year":"2004","journal-title":"Front. Biosci."},{"issue":"4","key":"10.1016\/j.msard.2019.101873_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1600-0404.2004.00207.x","article-title":"Nitric oxide synthase expression and enzymatic activity in multiple sclerosis","volume":"109","author":"Broholm","year":"2004","journal-title":"Acta. Neurol. Scand."},{"key":"10.1016\/j.msard.2019.101873_bib0006","first-page":"338","article-title":"Glutamate NMDA receptors in pathophysiology and pharmacotherapy of selected nervous system diseases","volume":"65","author":"Dobrek","year":"2011","journal-title":"Adv. Hyg. Experim. Med.\/Poste. Higie. Medy. Doswiad."},{"issue":"3","key":"10.1016\/j.msard.2019.101873_bib0007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/135245859800400323","article-title":"The potential role of nitric oxide in multiple sclerosis","volume":"4","author":"Giovannoni","year":"1998","journal-title":"Mul. Scler. J."},{"issue":"October","key":"10.1016\/j.msard.2019.101873_bib0008","first-page":"586","article-title":"Serum nitric oxide is increased in untreated multiple sclerosis patients","volume":"23","author":"Hallwirth","year":"2017","journal-title":"Mul. Scler. J."},{"issue":"4","key":"10.1016\/j.msard.2019.101873_bib0009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF03256329","article-title":"Disease biomarkers in multiple sclerosis","volume":"13","author":"Harris","year":"2009","journal-title":"Mol. Diagn. Ther."},{"issue":"6","key":"10.1016\/j.msard.2019.101873_bib0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40291-014-0117-0","article-title":"Biomarkers of therapeutic response in multiple sclerosis: current status","volume":"18","author":"Harris","year":"2014","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.msard.2019.101873_bib0011","first-page":"127","article-title":"Serum lactate and uric acid as biomarkers for disease activity and progression in multiple sclerosis","volume":"52","author":"Hassan","year":"2015","journal-title":"Egyp. J. Neur., Psy. Neuros."},{"issue":"1","key":"10.1016\/j.msard.2019.101873_bib0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00702-011-0686-6","article-title":"Serum nitric oxide concentrations in patients with multiple sclerosis and patients with epilepsy","volume":"119","author":"Ibragic","year":"2012","journal-title":"J. Neural. Transm."},{"issue":"11","key":"10.1016\/j.msard.2019.101873_bib0013","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2019.101873_bib0014","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.msard.2019.101873_bib0015","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/jnr.20285","article-title":"Nitric oxide from inflammatory\u2010activated glia synergizes with hypoxia to induce neuronal death","volume":"79","author":"Mander","year":"2005","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.msard.2019.101873_bib0016","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/1874205X01105010075","article-title":"Predictors of attack severity and duration in multiple sclerosis: a prospective study","volume":"5","author":"Naldi","year":"2011","journal-title":"Open Neurol. J."},{"issue":"5","key":"10.1016\/j.msard.2019.101873_bib0017","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1054\/jocn.2001.1077","article-title":"Serum nitric oxide metabolites in patients with multiple sclerosis","volume":"9","author":"Nazliel","year":"2002","journal-title":"J. cli. neurosci."},{"issue":"6","key":"10.1016\/j.msard.2019.101873_bib0018","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jprot.2010.01.004","article-title":"Multiple sclerosis: Identification and clinical evaluation of novel CSF biomarkers","volume":"73","author":"Ottervald","year":"2010","journal-title":"J. Proteomics."},{"issue":"8","key":"10.1016\/j.msard.2019.101873_bib0019","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/01.WNL.0000090564.88719.37","article-title":"Glutamate uptake by Oligodendrocytes Implications for excitotoxicity in multiple sclerosis","volume":"61","author":"Pitt","year":"2003","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2019.101873_bib0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2019.101873_bib0021","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/01.WNL.0000142043.32578.5D","article-title":"CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis","volume":"63","author":"Rejdak","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2019.101873_bib0022","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1352458507082061","article-title":"Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis","volume":"14","author":"Rejdak","year":"2008","journal-title":"Mul. Scler. J."},{"issue":"5","key":"10.1016\/j.msard.2019.101873_bib0023","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1471-4159.2004.02584.x","article-title":"Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor\u2010dependent and\u2010independent mechanisms","volume":"90","author":"Rosin","year":"2004","journal-title":"J. Neurochem."},{"issue":"8","key":"10.1016\/j.msard.2019.101873_bib0024","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archneur.60.8.1082","article-title":"Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid","volume":"60","author":"Sarchielli","year":"2003","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2019.101873_bib0025","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1179\/016164110X12816242542535","article-title":"Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome","volume":"33","author":"Sladkova","year":"2011","journal-title":"Neurol. Res."},{"issue":"4","key":"10.1016\/j.msard.2019.101873_bib0026","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1474-4422(02)00102-3","article-title":"The role of nitric oxide in multiple sclerosis","volume":"1","author":"Smith","year":"2002","journal-title":"The Lanc. Neurolog."},{"issue":"5","key":"10.1016\/j.msard.2019.101873_bib0027","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/brain\/awh467","article-title":"Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T","volume":"128","author":"Srinivasan","year":"2005","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.msard.2019.101873_bib0028","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1046\/j.1365-2362.1997.2250774.x","article-title":"Neurotransmitters in cerebrospinal fluid reflect pathological activity","volume":"27","author":"Stover","year":"1997","journal-title":"Eur. J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.msard.2019.101873_bib0029","doi-asserted-by":"crossref","first-page":"e61817","DOI":"10.1371\/journal.pone.0061817","article-title":"Increased concentrations of glutamate and glutamine in normal-appearing white matter of patients with multiple sclerosis and normal MR imaging brain scans","volume":"8","author":"Tisell","year":"2013","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.msard.2019.101873_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-510X(97)00183-4","article-title":"Changes in nitrite and nitrate (NO2\u2212\/NO3\u2212) levels in cerebrospinal fluid of patients with multiple sclerosis","volume":"153","author":"Yamashita","year":"1997","journal-title":"J. Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819309459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:53Z","timestamp":1761900413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819309459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"alternative-id":["S2211034819309459"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101873","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101873"}}